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An adequate level of the lignan enterolactone in the body may
provide protection against breast cancer. In accordance with this
hypothesis an elevated risk of breast cancer has been reported in
women with a low plasma enterolactone (Hulten et al, 1998) and
urinary enterolactone level (Adlercreutz et al, 1982; Ingram et al,
1997). Whole-grain products, berries and some vegetables
contribute to the enterolactone level in the body (Adlercreutz,
1998).
Enterolactone is produced by microbial transformation in the
gut from the plant precursors matairesinol and secoisolariciresinol
(Setchell et al, 1981; Borriello et al, 1985). There is a remarkable
variation in the ability of human subjects to produce enterolactone
from the precursors probably due to differences in bacterial
microflora (Adlercreutz and Mazur, 1997). Administration of
antibiotics or chemotherapeutics strongly reduced the entero-
lactone level in body fluids (Setchell et al, 1981; Adlercreutz et al,
1986) and long-term treatment with antibiotics could thus be a risk
factor for breast cancer. Bacteriuria is one of the most frequent
causes for such treatment in Finland. We have therefore studied
the effect of urinary tract infection, bacteriuria and antibacterial
treatment on breast cancer risk in the Finnish Mobile Clinic Health
Examination Survey cohort of 9461 women during an 
18-year follow-up period.
POPULATION AND METHODS
Between 1973 and 1977, the Finnish Mobile Clinic Health
Examination Survey carried out multiphasic health examinations
in 12 municipalities in four regions of Finland (Knekt et al, 1998).
In each of these four geographic regions, all inhabitants or a
random sample of inhabitants of one rural municipality and one
urban or semiurban municipality as well as the employees of one
factory were invited to attend the examination. A total of 9633
women 19–89 years of age participated in the examination.
All participants completed a premailed questionnaire checked at
the baseline examination. The questionnaire yielded information
on residence, education, marital status, smoking, number of child-
births, previous diseases and use of medication. Body height and
weight were measured at the baseline examination, and the body
mass index (weight (kg)/height2 (m2)) was calculated. Previous
history of a number of diseases was obtained using specific ques-
tions: ‘Have you had, according to a physician’s diagnosis,
cystitis, pyelonephritis, urinary tract infection or bacteria in the
urine?’ and, if yes: ‘Have you ever received medication for it?’
and ‘Are you taking medication for it at present?’ On the basis of
these questions, a category of previous or current antibacterial
treatment for urinary tract infection was defined. To study the
repeatability of the responses, a sample including 131 women was
re-examined after 6 months. The history of medical treatment for
urinary tract infection was well repeatable (kappa = 0.72).
In another part of the questionnaire, the participants were asked
to give the names of all the medications they had taken in the
previous 3 months. The preparations were categorized into the
main groups of the Finnish Remedia Fennica of 1974, including
12a: antibiotics proper (penicillins, streptomycin, chloramphenicol,
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12b: sulphonamides; and 12e: various other antimicrobial agents
(nitrofurantoin, nalidixate sodium, trimethoprim and its combina-
tions with sulphonamides). Among the 290 women who had
reported present use of medication for urinary tract infection, a
preparation from group 12b was indicated by 155 (53.4%), 12b or
12e by 282 (97.2%); and 12a, 12b or 12e by 289 (99.7%).
To screen for bacteriuria, all female participants gave midstream
urine samples. The presence of urinary bacteria was determined
using UricultR culture. Growth of >104 ml–1 was considered posi-
tive in the present study. At the 6-month re-examination, 33.5% of
the women who had been positive at the baseline screening were
found to have definite bacteriuria (growth of > 105 ml–1 of a patho-
genic organism), and these women were referred to care.
Information regarding cancer incidence during the follow-up
was obtained by linking data in the nationwide Finnish Cancer
Registry (Teppo et al, 1994) to the data of the study population.
Reporting to the Registry has been obligatory since 1961 and the
coverage of the Registry is practically complete. A total of 9461
women were at risk after exclusion of persons who had diagnosed
cancer before or during the baseline examination. During the
follow-up period from the 1973–1977 baseline examination to late
1991, 157 female breast cancer cases (World Health Organization,
1955) were diagnosed.
The Cox proportional hazards model was used to estimate the
association between treatment for urinary tract infection and the
incidence of breast cancer (Cox, 1972). Adjustment for potential
confounding factors was performed by including these in the
models. Interaction terms between antibacterial medication and
age were also included. Relative risks between users and nonusers
of antibacterial medication were estimated, based on the models.
RESULTS
Those women who developed breast cancer during the 18-year-
long follow-up period were older, more often from urban or indus-
trial areas, had a higher level of education, were leaner and taller,
had a smaller number of childbirths and consumed more alcohol
than women not developing the disease (Table 1). Although no
elevation in the incidence of breast cancer was noted in women
who were screening positive for bacteriuria at baseline, those with
a previous history of antibacterial treatment for bacteriuria showed
a relative risk (RR) for the neoplasm of 1.34 (95% confidence
interval (CI) 0.98–1.83) in comparison with other women. The
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Table 1 Relative riska (95% confidence interval) of breast cancer between categories of potential risk factors
Factor Category No. of No. at Relative 95% confidence
cases risk risk interval
Age <30 10 2065 1
30–39 34 1830 3.76 1.86–7.62
40–49 43 1786 4.97 2.50–9.88
50–59 27 1726 3.44 1.66–7.10
60–69 28 1361 5.49 2.67–11.32
³70 15 693 9.06 4.05–20.25
Region type Urban 85 4423 1
Agriculture 41 3637 0.55 0.38–0.80
Industry 31 1401 0.96 0.63–1.47
Education Low 97 6253 1
Intermediate 45 2578 1.49 1.03–2.16
High 15 589 1.92 1.11–3.32
Marital status Unmarried 27 1712 1
Married 101 6150 0.88 0.57–1.34
Divorced 24 1235 0.78 0.43–1.42
Widowed 5 362 0.70 0.27–1.82
Body mass index <22.5 49 3015 1
22.5–24.9 39 2102 0.88 0.57–1.35
25.0–27.4 24 1689 0.59 0.36–0.99
27.5–29.9 21 1186 0.69 0.40–1.89
³30 24 1468 0.61 0.36–1.03
Parity Nulliparous 40 2296 1
1–2 70 3740 0.97 0.66–1.43
³3 47 3425 0.59 0.38–0.90
Smoking Never 135 7342 1
Ex 6 667 0.59 0.26–1.34
Current 13 1429 0.71 0.41–1.22
Height quartile <156 38 2493 1
156–159 39 2246 1.25 0.80–1.97
160–163 36 2224 1.29 0.80–2.06
³164 44 2497 1.57 0.98–2.51
Alcohol use 0 102 5695 1
1–249 39 3112 0.85 0.58–1.26
³250 16 627 1.99 1.14–3.47
Screening No 138 8329 1
positive to Yes 18 954 1.12 0.68–1.83
bacteriuria
Antibacterial No 79 5369 1
treatment Yes 78 4092 1.34 0.98–1.83
aAge-adjusted.cross-product of antibacterial treatment for bacteriuria and
screening positive for bacteriuria confirmed this observation
(Table 2). Those women previously treated for urinary tract infec-
tion and accordingly having no bacteriuria at baseline showed a
RR of 1.35 (95% CI 0.96–1.87), whereas untreated women with
newly diagnosed bacteriuria showed a RR of 1.18 (95% CI
0.57–2.45).
The associations between history of antibacterial treatment and
breast cancer incidence varied considerably among age-groups.
They were strongest in women under 40 years of age, were contin-
uously reduced as a function of age and were lowest among
women aged 60 years or more. The RR (history of antibacterial
treatment positive vs negative) for the age-groups < 40 years,
40–49 years, 50–59 years and 60–69 years were 1.92 (95% CI
1.05–3.50), 1.46 (95% CI 0.80–2.66), 1.25 (95% CI 0.59–2.66)
and 0.87 (95% CI 0.47–1.59) respectively.
With few exceptions, only weak associations existed between
the history of antibacterial treatment for urinary tract infection and
known potential risk factors of breast cancer, i.e. regional type,
educational level, marital status, body mass index, height, parity
and alcohol use. The strongest association was observed with
parity, with a considerably low prevalence of antibacterial treat-
ment among nulliparous women (data not shown). Accordingly,
the relative risk for breast cancer among women who had received
antibacterial treatment for urinary tract infection in comparison
with those not receiving treatment was not notably altered by
further adjustment for these factors (Table 3). The RR was 1.31
(95% CI 0.95–1.81) in all age-groups and 1.74 (95% CI
1.13–2.68) in women under 50 years of age.
The association between history of antibacterial treatment and
breast cancer incidence was dependent on the length of follow-up
(Table 3). It was strongest among women under 50 years of age
with follow-up times of over 10 years; the RR was 1.93 (95% CI
1.11–3.37). No significant association was observed during the
first 10 years of follow-up.
DISCUSSION
The results of the present study suggest that premenopausal
women using antibacterial treatment for bacteriuria have an
elevated risk of developing breast cancer. A 74% excess risk was
observed among women under 50 years of age, whereas no excess
risk was noted among older women. The highest excess risk, 93%,
was observed after a 10-year follow-up. These findings suggest
that those women developing breast cancer are exposed to antibac-
terial medication at a relatively young age and that development of
the disease requires more than 10 years. The follow-up period
needed to demonstrate the association was relatively long. Since
the long follow-up tends to weaken the representativeness of data
on the antibacterial medication due to changes over time in use and
type of antibiotics and chemotherapeutics, the excess risk found
may be a conservative estimate. Furthermore, antibiotics are also
commonly used for other reasons, which reduces contrast between
the groups.
At the time of baseline examination, bacteriuria was considered
potentially deleterious for kidneys, dysuria was regarded as a
serious symptom and long period of medication followed by
subsequent checkup were generally recommended. In the present
study the history of antibacterial medication was based on ques-
tions about previous infections of the urinary tract, whereas data
on neither the amounts of specific medication used nor on duration
of use were available. These caveats, however, probably result in
conservative estimates of the relative risks. The information on
treatment for bacteriuria appeared to be valid since in the
subsample of women with ongoing treatment, 97% reported the
use of sulphonamides or combinations of such medications that
were usually prescribed for bacteriuria at that time in Finland. The
information on previous medication was also reliable since its
repeatability after 6 months was relatively good. Although no
meaningful hypothesis exists (Barnett and Stephens, 1997), the
possibility cannot be fully excluded that the infection or some of
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Table 2 Relative riska (95% confidence interval) of breast cancer between women with history of antibacterial treatment for bacteriuria and other women in
categories of baseline screening for bacteriuria
Baseline History of antibacterial medication for urinary tract infections
screening for No Yes
bacteriuria No. at risk No. of cases RR 95% CI No. at risk No. of cases RR 95% CI
Negative 4811 70 1 – 3518 68 1.34 0.96–1.87
Positive 456 8 1.18 0.57–2.45 498 10 1.37 0.71–2.67
aAge-adjusted.
Table 3 Relative riska (95% confidence interval) of breast cancer between women with history of antibacterial treatment for bacteriuria and other women, by
age and length of follow-up
Age (years)
Follow-up 0–49 (5536)b 50–99 (3654)b Total (9190)b
(years) No. of cases RR 95% CI No. of cases RR 95% CI No. of cases RR 95% CI
1–10 33 1.47 0.73–2.97 37 1.14 0.59–2.22 70 1.24 0.77–1.99
11–18 53 1.93 1.11–3.37 32 0.78 0.37–1.67 85 1.37 0.89–2.12
Total 86 1.74 1.13–2.68 69 0.97 0.59–1.58 155 1.31 0.95–1.81
aAdjusted for age, region type, education, marital status, body mass index, parity, smoking, height, alcohol use and screening positive for bacteriuria.
bWomen at risk.its risk factors rather than the antibacterial treatment is the risk
factor. The finding that baseline bacteriuria per se was not associ-
ated with subsequent breast cancer incidence, however, conflicts
with that suggestion.
In accordance with findings from several previous studies
(Harris et al, 1992), we found an elevated risk of breast cancer
among women living in urban or industrial areas, having a higher
level of education, with low parity, low body mass index and
higher stature and among women using alcohol. It is thus plausible
to expect that our finding of an independently elevated risk of
breast cancer among young women who have received antibacte-
rial treatment is also reliable. Since family disposition to breast
cancer, age at menarche, age at birth of first child, age at
menopause, benign breast disease, oral contraceptive use and post-
menopausal oestrogen-replacement therapy, all of which are estab-
lished or probable risk factors for breast cancer (Hulten et al,
1998), were not available in the present study, the association may
be due to uncontrolled confounding. Dietary variables were also
not available. On the other hand, it is reasonable to hypothesize
that none of the risk factors mentioned are associated with bacteri-
uria or its treatment, and thus the antibacterial treatment/breast
cancer relation may not be affected by adjustment for these
factors.
In summary, we found an elevated risk of breast cancer in
women who had received antibacterial treatment for urinary tract
infection at a premenopausal age. This provides indirect sugges-
tive evidence on the role of low lignan status in breast cancer
development. Although our finding is biologically plausible and
was independent of other risk factors for breast cancer available,
the potential importance of uncontrolled factors in the relation
cannot be excluded. Results from further observational epidemio-
logical studies are needed before serious suspicions can be
proposed about the involvement of antibiotics or chemothera-
peutics in the aetiology of breast cancer.
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